• Report from the ESMO 2018 presidential symposium-Radiotherapy to the primary tumour for men with newly diagnosed metastatic prostate cancer: survival results from STAMPEDE. 

  Parker, C (2018)
• Adverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivors. 

  Abu Zaid, M; Dinh, PC; Monahan, PO; Fung, C; El-Charif, O; Feldman, DR; Hamilton, RJ; Vaughn, DJ; Beard, CJ; Cook, R; Althouse, S; Ardeshir-Rouhani-Fard, S; Sesso, HD; Huddart, R; Mushiroda, T; Kubo, M; Dolan, ME; Einhorn, LH; Fossa, SD; Travis, LB; Platinum Study Group (2019-05-01)

  BACKGROUND: This study examined the prevalence of hypogonadism, its clinical and genetic risk factors, and its relationship to adverse health outcomes (AHOs) in North American testicular cancer survivors (TCS) after modern ...
• Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment. 

  Evgin, L; Huff, AL; Kottke, T; Thompson, J; Molan, AM; Driscoll, CB; Schuelke, M; Shim, KG; Wongthida, P; Ilett, EJ; Smith, KK; Harris, RS; Coffey, M; Pulido, JS; Pandha, H; Selby, PJ; Harrington, KJ; Melcher, A; Vile, RG

  Antitumor T-cell responses raised by first-line therapies such as chemotherapy, radiation, tumor cell vaccines, and viroimmunotherapy tend to be weak, both quantitatively (low frequency) and qualitatively (low affinity). ...
• Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study. 

  Brown, LC; Ahmed, HU; Faria, R; El-Shater Bosaily, A; Gabe, R; Kaplan, RS; Parmar, M; Collaco-Moraes, Y; Ward, K; Hindley, RG; Freeman, A; Kirkham, A; Oldroyd, R; Parker, C; Bott, S; Burns-Cox, N; Dudderidge, T; Ghei, M; Henderson, A; Persad, R; Rosario, DJ; Shergill, I; Winkler, M; Soares, M; Spackman, E; Sculpher, M; Emberton, M

  BACKGROUND: Men with suspected prostate cancer usually undergo transrectal ultrasound (TRUS)-guided prostate biopsy. TRUS-guided biopsy can cause side effects and has relatively poor diagnostic accuracy. Multiparametric ...
• From Clinical Trials to Real-life Clinical Practice: The Role of Immunotherapy with PD-1/PD-L1 Inhibitors in Advanced Urothelial Carcinoma. 

  Hussain, SA; Birtle, A; Crabb, S; Huddart, R; Small, D; Summerhayes, M; Jones, R; Protheroe, A

  CONTEXT: A number of PD-1/PD-L1 inhibitors have recently been approved for use in patients with locally advanced or metastatic urothelial carcinoma (UC) on the basis of results from several clinical trials. OBJECTIVE: To ...
• The Dandelion Dilemma Revisited for Oligoprogression: Treat the Whole Lawn or Weed Selectively? 

  Patel, PH; Palma, D; McDonald, F; Tree, AC (2019-06-07)

  Oligoprogressive disease is a relatively new clinical concept describing progression at only a few sites of metastasis in patients with otherwise controlled widespread disease. In the era of well-tolerated targeted treatments, ...
• This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols. 

  Schiavone, F; Bathia, R; Letchemanan, K; Masters, L; Amos, C; Bara, A; Brown, L; Gilson, C; Pugh, C; Atako, N; Hudson, F; Parmar, M; Langley, R; Kaplan, RS; Parker, C; Attard, G; Clarke, NW; Gillessen, S; James, ND; Maughan, T; Sydes, MR; past and present members of the STAMPEDE and FOCUS4 Trial Management Group (2019-05-29)

  BACKGROUND: There are limited research and literature on the trial management challenges encountered in running adaptive platform trials. This trial design allows both (1) the seamless addition of new research comparisons ...
• Radiogenomics Consortium Genome-Wide Association Study Meta-analysis of Late Toxicity after Prostate Cancer Radiotherapy. 

  Kerns, SL; Fachal, L; Dorling, L; Barnett, GC; Baran, A; Peterson, DR; Hollenberg, M; Hao, K; Narzo, AD; Ahsen, ME; Pandey, G; Bentzen, SM; Janelsins, M; Elliott, RM; Pharoah, PDP; Burnet, NG; Dearnaley, DP; Gulliford, SL; Hall, E; Sydes, MR; Aguado-Barrera, ME; Gómez-Caamaño, A; Carballo, AM; Peleteiro, P; Lobato-Busto, R; Stock, R; Stone, NN; Ostrer, H; Usmani, N; Singhal, S; Tsuji, H; Imai, T; Saito, S; Eeles, R; DeRuyck, K; Parliament, M; Dunning, AM; Vega, A; Rosenstein, BS; West, CML (2019-05-16)

  BACKGROUND: 10-20% of patients develop long-term toxicity following radiotherapy for prostate cancer. Identification of common genetic variants associated with susceptibility to radiotoxicity might improve risk prediction ...
• Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness. 

  Woods, BS; Sideris, E; Sydes, MR; Gannon, MR; Parmar, MKB; Alzouebi, M; Attard, G; Birtle, AJ; Brock, S; Cathomas, R; Chakraborti, PR; Cook, A; Cross, WR; Dearnaley, DP; Gale, J; Gibbs, S; Graham, JD; Hughes, R; Jones, RJ; Laing, R; Mason, MD; Matheson, D; McLaren, DB; Millman, R; O'Sullivan, JM; Parikh, O; Parker, CC; Peedell, C; Protheroe, A; Ritchie, AWS; Robinson, A; Russell, JM; Simms, MS; Srihari, NN; Srinivasan, R; Staffurth, JN; Sundar, S; Thalmann, GN; Tolan, S; Tran, ATH; Tsang, D; Wagstaff, J; James, ND; Sculpher, MJ

  BACKGROUND: Results from large randomised controlled trials have shown that adding docetaxel to the standard of care (SOC) for men initiating hormone therapy for prostate cancer (PC) prolongs survival for those with ...
• A Tool for Shared Decision Making on Referral for Prostate Biopsy in the Primary Care Setting: Integrating Risks of Cancer with Life Expectancy. 

  Verbeek, JFM; Nieboer, D; Parker, C; Kattan, MW; Steyerberg, EW; Roobol, MJ (2019-04-22)

  Prostate cancer (PCa) testing involves a complex individually based decision making process. It should consider competing risks from other comorbidities when estimating a survival benefit from the early detection of ...
• Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer. 

  Gulley, JL; Borre, M; Vogelzang, NJ; Ng, S; Agarwal, N; Parker, CC; Pook, DW; Rathenborg, P; Flaig, TW; Carles, J; Saad, F; Shore, ND; Chen, L; Heery, CR; Gerritsen, WR; Priou, F; Langkilde, NC; Novikov, A; Kantoff, PW (2019-05-01)

  PURPOSE: PROSTVAC, a viral vector-based immunotherapy, prolonged median overall survival (OS) by 8.5 months versus placebo in metastatic castration-resistant prostate cancer in a phase II study. This phase III study further ...
• Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis. 

  Burdett, S; Boevé, LM; Ingleby, FC; Fisher, DJ; Rydzewska, LH; Vale, CL; van Andel, G; Clarke, NW; Hulshof, MC; James, ND; Parker, CC; Parmar, MK; Sweeney, CJ; Sydes, MR; Tombal, B; Verhagen, PC; Tierney, JF; STOPCAP M1 Radiotherapy Collaborators (2019-02-27)

  BACKGROUND: Many trials are evaluating therapies for men with metastatic hormone-sensitive prostate cancer (mHSPC). OBJECTIVE: To systematically review trials of prostate radiotherapy. DESIGN, SETTING, AND PARTICIPANTS: ...
• Catalytic inhibition of KDM1A in Ewing sarcoma is insufficient as a therapeutic strategy. 

  Romo-Morales, A; Aladowicz, E; Blagg, J; Gatz, SA; Shipley, JM (2019-06-17)

  BACKGROUND: Ewing sarcoma and desmoplastic small round cell tumors (DSRCT) are rare and clinically aggressive sarcomas usually characterized by oncogenic fusion proteins involving EWS. Emerging studies of Ewing sarcoma ...
• Pharmacodynamic and clinical results from a phase 1/2 study of the HSP90 inhibitor onalespib in combination with abiraterone acetate in prostate cancer. 

  Slovin, SF; Hussain, S; Saad, F; Garcia, JA; Picus, J; Ferraldeschi, R; Crespo, M; Flohr, PR; Riisnaes, R; Lin, C; Keer, H; Oganesian, A; Workman, P; de Bono, JS (2019-05-21)

  PURPOSE: Onalespib is a potent, fragment-derived second-generation HSP90 inhibitor with preclinical activity in castration-resistant prostate cancer (CPRC) models. This Phase 1/2 trial evaluated onalespib in combination ...
• Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition. 

  Jennings, VA; Scott, GB; Rose, AMS; Scott, KJ; Migneco, G; Keller, B; Reilly, K; Donnelly, O; Peach, H; Dewar, D; Harrington, KJ; Pandha, H; Samson, A; Vile, RG; Melcher, AA; Errington-Mais, F (2019-06-05)

  A clinical oncolytic herpes simplex virus (HSV) encoding granulocyte-macrophage colony-stimulating factor (GM-CSF), talimogene laherparepvec, causes regression of injected and non-injected melanoma lesions in patients and ...
• Night shift work and risk of breast cancer in women: the Generations Study cohort. 

  Jones, ME; Schoemaker, MJ; McFadden, EC; Wright, LB; Johns, LE; Swerdlow, AJ (2019-05-29)

  BACKGROUND: It is plausible that night shift work could affect breast cancer risk, possibly by melatonin suppression or circadian clock disruption, but epidemiological evidence is inconclusive. METHODS: Using serial ...
• Metabolic adaptability in metastatic breast cancer by AKR1B10-dependent balancing of glycolysis and fatty acid oxidation 

  Isacke, C
• The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models. 

  Martínez-Vélez, N; Garcia-Moure, M; Marigil, M; González-Huarriz, M; Puigdelloses, M; Gallego Pérez-Larraya, J; Zalacaín, M; Marrodán, L; Varela-Guruceaga, M; Laspidea, V; Aristu, JJ; Ramos, LI; Tejada-Solís, S; Díez-Valle, R; Jones, C; Mackay, A; Martínez-Climent, JA; García-Barchino, MJ; Raabe, E; Monje, M; Becher, OJ; Junier, MP; El-Habr, EA; Chneiweiss, H; Aldave, G; Jiang, H; Fueyo, J; Patiño-García, A; Gomez-Manzano, C; Alonso, MM (2019-05-28)

  Pediatric high-grade glioma (pHGG) and diffuse intrinsic pontine gliomas (DIPGs) are aggressive pediatric brain tumors in desperate need of a curative treatment. Oncolytic virotherapy is emerging as a solid therapeutic ...
• Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia. 

  Craddock, C; Slade, D; De Santo, C; Wheat, R; Ferguson, P; Hodgkinson, A; Brock, K; Cavenagh, J; Ingram, W; Dennis, M; Malladi, R; Siddique, S; Mussai, F; Yap, C (2019-03-01)

  PURPOSE: Salvage options for patients who relapse after allogeneic stem-cell transplantation (allo-SCT) for acute myeloid leukemia (AML) and myelodysplasia (MDS) remain limited, and novel treatment strategies are required. ...
• How to design a dose-finding study using the continual reassessment method. 

  Wheeler, GM; Mander, AP; Bedding, A; Brock, K; Cornelius, V; Grieve, AP; Jaki, T; Love, SB; Odondi, L; Weir, CJ; Yap, C; Bond, SJ (2019-01-18)

  INTRODUCTION: The continual reassessment method (CRM) is a model-based design for phase I trials, which aims to find the maximum tolerated dose (MTD) of a new therapy. The CRM has been shown to be more accurate in targeting ...

View more